Ogden Christopher

CIK 00019145231 companySOUTH SAN FRANCISCO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001914523

Recent Transactions

31 trades

Award
CytomX Therapeutics, Inc.$CTMX
Common Stock
2026-02-02+90,000→ 316,271 total
Award
CytomX Therapeutics, Inc.$CTMX
Stock Option (Right to Buy)
2026-02-02+325,000→ 325,000 total
Award
CytomX Therapeutics, Inc.$CTMX
Performance Stock Units (PSUs)
2025-09-26+39,150→ 39,150 total
Award
CytomX Therapeutics, Inc.$CTMX
Stock Option (Right to Buy)
2025-09-26+78,250→ 78,250 total
Sale
CytomX Therapeutics, Inc.$CTMX
Common Stock
2025-06-16$2.69/sh−10,614→ 226,271 total
Sale
CytomX Therapeutics, Inc.$CTMX
Common Stock
2025-06-13$2.95/sh−1,641→ 199,385 total
Exercise/Conversion
CytomX Therapeutics, Inc.$CTMX
Performance Stock Units
2025-06-13−37,500→ 0 total
Exercise/Conversion
CytomX Therapeutics, Inc.$CTMX
Common Stock
2025-06-13+37,500→ 236,885 total
Sale
CytomX Therapeutics, Inc.$CTMX
Common Stock
2025-03-18$0.60/sh−8,551→ 201,026 total
Award
CytomX Therapeutics, Inc.$CTMX
Common Stock
2025-02-04+44,000→ 152,077 total
Award
CytomX Therapeutics, Inc.$CTMX
Stock Option (Right to Buy)
2025-02-04+115,000→ 115,000 total
Award
CytomX Therapeutics, Inc.$CTMX
Common Stock
2025-02-04+57,500→ 209,577 total
Award
CytomX Therapeutics, Inc.$CTMX
Stock Option (Right to Buy)
2025-02-04+225,000→ 225,000 total
Exercise/Conversion
CytomX Therapeutics, Inc.$CTMX
Performance Stock Units (PSUs)
2024-08-20−6,875→ 0 total
Exercise/Conversion
CytomX Therapeutics, Inc.$CTMX
Common Stock
2024-08-20+6,875→ 110,061 total
Sale
CytomX Therapeutics, Inc.$CTMX
Common Stock
2024-08-20$1.23/sh−1,984→ 108,077 total
Award
CytomX Therapeutics, Inc.$CTMX
Stock Option (Right to Buy)
2024-06-12+75,000→ 75,000 total
Award
CytomX Therapeutics, Inc.$CTMX
Common Stock
2024-06-12+17,500→ 103,186 total
Sale
CytomX Therapeutics, Inc.$CTMX
Common Stock
2024-03-19$2.09/sh−2,971→ 85,686 total
Award
CytomX Therapeutics, Inc.$CTMX
Common Stock
2024-01-18+40,000→ 88,657 total
Award
CytomX Therapeutics, Inc.$CTMX
Stock Option (Right to Buy)
2024-01-18+154,000→ 154,000 total
Award
CytomX Therapeutics, Inc.$CTMX
Performance Stock Units (PSUs)
2024-01-18+75,000→ 75,000 total
Sale
CytomX Therapeutics, Inc.$CTMX
Common Stock
2023-12-20$1.38/sh−1,990→ 48,657 total
Exercise/Conversion
CytomX Therapeutics, Inc.$CTMX
Common Stock
2023-12-17+6,875→ 50,647 total
Exercise/Conversion
CytomX Therapeutics, Inc.$CTMX
Performance Stock Units (PSUs)
2023-12-17−6,875→ 6,875 total
Sale
CytomX Therapeutics, Inc.$CTMX
Common Stock
2023-03-16$1.98/sh−516→ 37,772 total
Award
CytomX Therapeutics, Inc.$CTMX
Performance Stock Units (PSUs)
2023-02-02+75,000→ 75,000 total
Award
CytomX Therapeutics, Inc.$CTMX
Stock Option (Right to Buy)
2023-02-02+75,000→ 75,000 total
Award
CytomX Therapeutics, Inc.$CTMX
Common Stock
2023-02-02+25,000→ 38,288 total
Award
CytomX Therapeutics, Inc.$CTMX
Performance Stock Units (PSUs)
2022-08-10+13,750→ 13,750 total
Award
CytomX Therapeutics, Inc.$CTMX
Stock Option (Right to Buy)
2022-08-10+82,500→ 82,500 total

Companies

CytomX Therapeutics, Inc.
Chief Financial Officer
$CTMX

Recent Filings

Address

C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., SUITE 400

SOUTH SAN FRANCISCO, CA, 94080

View on SEC.gov